BioNTech’s Oncology Ambitions Advance with Promising Breast Cancer Trial Data

BioNTech SE has achieved a significant milestone in its oncology pipeline, with a novel breast cancer therapy demonstrating superior results in a pivotal late-stage trial. The development marks a crucial step for the Mainz-based company as it seeks to diversify beyond its COVID-19 vaccine success and establish itself in the competitive cancer therapeutics market.

The company, alongside its Chinese collaborator DualityBio, announced on September 5th that their investigational drug candidate, BNT323 (also known as Trastuzumab Pamirtecan), met its primary endpoint in a Phase 3 trial. The study focused on patients with HER2-positive metastatic or inoperable breast cancer, a difficult-to-treat population. An independent data monitoring committee confirmed that patients receiving the BioNTech therapy experienced a longer period without disease progression compared to those on Roche’s established standard of care, Kadcyla.

This outcome represents a historic validation for BioNTech, being the company’s first late-stage oncology program to yield positive topline results with a clear pathway toward potential regulatory approval. The news was met with strong investor enthusiasm, propelling the company’s shares upward by nearly 10 percent.

The successful candidate originates from a strategic licensing agreement BioNTech entered with DualityBio in April 2023. In a deal valued at up to $1.67 billion, which included a $170 million upfront payment, BioNTech secured global rights to develop and commercialize two antibody-drug conjugates, including BNT323. The drug utilizes DualityBio’s proprietary DITAC platform technology to precisely target HER2-positive tumors.

“This achievement is a testament to the productive collaboration between our teams,” commented BioNTech co-founder Özlem Türeci.

Should investors sell immediately? Or is it worth buying BioNTech?

With this positive data, BioNTech is now positioned to challenge entrenched competitors in a multi-billion dollar market. Rival therapies, such as the blockbuster drug Enhertu developed by AstraZeneca and Daiichi Sankyo, currently hold a dominant market position.

Market analysts have reacted positively to the development. Sushila Hernandez, an analyst at Van Lanschot Kempen, noted, “It is exciting that this is BioNTech’s first late oncology program to hit its primary endpoint.” Attention now turns to the forthcoming complete data set and the progress of a parallel global Phase 3 trial, the results of which will be critical for securing marketing authorization in the United States and European Union.

Furthermore, the partners are testing BNT323 in a separate trial for a broader patient group with HER2-low expressing breast cancer, a success that could substantially expand the drug’s addressable market.

On the regulatory front, DualityBio has announced plans to initiate discussions with Chinese health authorities. The U.S. Food and Drug Administration (FDA) has already granted the therapy both Fast Track and Breakthrough Therapy designations for the treatment of endometrial cancer, indicating a potential pathway for an accelerated review process.

Financially, BioNTech is well-equipped to advance its oncology portfolio, boasting a cash reserve of €16 billion. Investors are anticipated to look for further details on the company’s broader cancer strategy beyond mRNA technology when BioNTech releases its next quarterly report on November 3rd.